Company intelligence / Profile preview

L Berg

Framingham, Massachusetts, United Statespaulweiss.com ↗

Ownership: Private
Development stage: Other

Overview

BERG developed an AI-driven platform to identify novel disease targets and biomarkers. Its lead asset BPM31510 is in phase 2 trials for glioblastoma multiforme and pancreatic cancer with orphan drug designations. The company also advanced a topical formulation of BPM31510 into rare pediatric disease indications. Other pipeline assets are at preclinical or discontinued stages.

Therapeutic areas: OncologyHematology
Modalities: Small moleculeProtein drugs (including coenzyme Q10, monoclonal antibodies)
Industry: Biotech

Partnerships

AstraZenecaBoehringer IngelheimUniversity of Oxford collaboration via BPGbio post-acquisition

Beyond the preview

Go deeper on L Berg.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on L Berg.

Explore the full profile